Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01892189 · ClinicalTrials.gov registry record · Phase 1
Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT01892189 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 27 participants.
The verdict
NCT01892189, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether ketamine-induced brain activity changes are modulated by TAK-063 administration using neuroimaging battery tests.
Interventions
- DRUG Ketamine
- DRUG TAK-063
- DRUG TAK-063 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2013-08 |
| Est. Completion | 2014-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01892189
The ClinicalTrials.gov registry entry for NCT01892189 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ketamine is the first listed.
NCT01892189 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01892189 about?
NCT01892189 is a clinical study titled "Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults". The purpose of this study is to determine whether ketamine-induced brain activity changes are modulated by TAK-063 administration using neuroimaging battery tests.
What is the current status of trial NCT01892189?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2013-08. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01892189?
The interventions under investigation include: Ketamine (DRUG), TAK-063 (DRUG), TAK-063 Placebo (DRUG).
Who is sponsoring clinical trial NCT01892189?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.